Merck (MRK) EPS (Basic) Growth (3y) (2012 - 2026)
Merck (MRK) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -34.06% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -35.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.72% |
| Mar 31, 2026 | -52.26% |
| Dec 31, 2024 | 302.91% |
| Jun 30, 2024 | 154.29% |
| Mar 31, 2024 | 122.23% |
| Dec 31, 2023 | -63.09% |
| Sep 30, 2023 | 97.04% |
| Jun 30, 2023 | -121.98% |
| Mar 31, 2023 | -4.32% |
| Dec 31, 2021 | -26.72% |
| Jun 30, 2021 | -41.04% |
| Mar 31, 2021 | -14.56% |
| Dec 31, 2020 | 36.51% |
| Sep 30, 2020 | 147.10% |
| Jun 30, 2020 | -28.29% |
| Mar 31, 2020 | 30.88% |
| Dec 31, 2019 | -49.20% |
| Sep 30, 2019 | -1.97% |
| Jun 30, 2019 | 32.98% |
| Mar 31, 2019 | 39.56% |